|Other Names||Serine/threonine-protein kinase 17B, DAP kinase-related apoptosis-inducing protein kinase 2, STK17B, DRAK2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7221b was selected from the C-term region of human DRAK2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis.|
|Cellular Location||Nucleus. Cell membrane. Endoplasmic reticulum-Golgi intermediate compartment. Note=Colocalizes with STK17B at the plasma membrane.|
|Tissue Location||Highly expressed in placenta, lung, pancreas. Lower levels in heart, brain, liver, skeletal muscle and kidney|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.
Sanjo, H., et al., J. Biol. Chem. 273(44):29066-29071 (1998).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.